HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer

about

HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer

Item

http://www.wikidata.org/entity/Q57109545

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@en

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@nl

type

Item

label

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@en

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@nl

prefLabel

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@en

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@nl

P1476

HER2 inhibition in gastro-oeso ...... ons learned from breast cancer

@en

P2093

Hazel Lote

http://www.w3.org/2001/XMLSchema#string

Ian Chau

http://www.w3.org/2001/XMLSchema#string

P2860

Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

P304

159-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4251/WJGO.V10.I7.159

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Valeri

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30079142

http://www.w3.org/2001/XMLSchema#string

P932

6068859

http://www.w3.org/2001/XMLSchema#string